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ABSTRACT 
Italy is amongst the European countries with the lowest uptake of generic medicines. This paper 
provides a perspective on the Italian generic medicines retail market and how the current policy 
environment may affect the long-term sustainability. Fast market entrance of generic medicines in Italy 
is hindered by several factors: the existence of Complementary Protection Certificates in the past, the 
large market for copies and multiple cases of patent linkage. Prices of generic medicines in Italy are 
low compared to other European countries. Whereas in the past the Italian government introduced 
mandatory price cuts on generic medicines to contain pharmaceutical expenditures, pharmaceutical 
companies are currently forced to paybacks in case of overspending. As these paybacks are 
calculated per pharmaceutical company on their level of expenditures during last year, these paybacks 
are disproportionally penalizing small and fast growing companies, to which most generic companies 
belong to. The Italian government has already implemented different policies to increase the use of 
generic medicines. However, these policies seem to be insufficient to effectively increase the 
prescribing, dispensing or asking for generic medicines in Italy. The current market environment 
surrounding generic medicines in Italy (i.e. low prices, low volumes) threatens the long-term 
sustainability of the Italian generic medicines market. Recommendations to increase the sustainability 
of the Italian generic medicines retail market round off this perspective paper. 
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KEY ISSUES 
• The use of generic medicines in Italy is low compared to other European countries. 
• This paper aims to provide a perspective on the Italian generic medicines retail market and 
how the current policy environment may affect the long-term sustainability. 
• The current regulatory framework in Italy does not support the development of a generic 
medicines market. 
• Patent linkage has been a long-standing barrier for uptake of generic medicines in Italy and 
still remains a problem. 
• The current payback system for pharmaceutical companies in case of overspending of the 
pharmaceutical retail budget disproportionally targets generic medicines companies. 
• The concentration on the prices of generic medicines in combination with the limited diffusion 
of generic medicines in Italy may threaten the long-term sustainability. 
• There is a lack of effective demand-side policies in Italy targeted at physicians, pharmacists 
and patients. 
• The Italian government must take action to ensure the long-term sustainability of the Italian 
generic medicines retail market. Recommendations to increase the use of generic medicines 
are suggested at the end of this perspective paper. 
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INTRODUCTION 
The Italian health care system is a regionally based, tax-funded National Health Service (NHS) which 
provides uniform and comprehensive health care for the entire population free of charge at point of 
service [1-3]. Organization of health care is split up into three tiers: the Central government at national 
level; 21 regional governments at regional level; and 195 local health units (“Aziende Sanitarie Locali”) 
and 147 independent hospitals and university hospitals at local level [1;2;4]. The NHS is financed by 
national and regional taxes (97%) and patient co-payments. The health care budget is annually 
established at national level by the Budget Law (“Legge Finanziaria”), after which the available budget 
is allocated among the regions, mostly on an age-adjusted capitation basis [1].  
A shifting of powers from the federal level to the 21 regions over the last decade has also affected the 
pharmaceutical sector. The Central government, by means of the Italian Medicines Agency (AIFA), 
remains in charge of regulating the market and monitoring the consumption of pharmaceuticals. Their 
responsibilities include marketing authorization, pricing, reimbursement and pharmacovigilance of all 
pharmaceuticals. Regional health care authorities have to work within the legislative framework as 
defined by the Central government. Their responsibilities include the promoting of efficiency and 
quality in their region as well as the controlling of pharmaceutical expenditures. Additional policies 
related to pharmaceuticals can be implemented autonomously by local health care authorities. Actual 
health services to the population are provided by local health units and hospitals, under the 
supervision of the regional health care authorities [1;2;4;5]. 
Italy is the third largest pharmaceutical market in Europe with a total expenditure of around €24.87bn 
[6]. In 2012, total health expenditure accounted for 9.2% of the GDP and 15.7% of this expenditure 
was spent on pharmaceuticals [7]. Pharmaceutical expenditure has been decreasing over the last 
decade, and this trend has only intensified considerably in response to the worldwide financial and 
economic crisis, which has hit Italy drastically. For instance, pharmaceutical expenditure in Italy 
decreased by around 9% over the period 2010-2011, while the European decline was only around 
2.6% on average [7;8]. 
Italy has traditionally been one of the countries with the lowest uptake of generic medicines in Europe, 
as shown in Figure 1 [7]. In 2013, generic medicines represented 18% of the total pharmaceutical 
market by volume and 9,52% by value [Personal communication Assogenerici]. Due to the regionalization of 
5 
 
health care, generic market shares by volume vary considerably among the regions, as highlighted in 
Figure 2 [9]. With the off-patent market in Italy accounting for 65.66% of the total pharmaceutical 
market and generic medicines only accounting for 26.96% of this market, the potential for generic 
medicines in Italy is still substantial [9]. 
[Insert Figure 1 and 2 about here] 
The aims of this report are to provide a perspective on the Italian generic medicines retail market. 
Barriers to the development of a more mature and sustainable generic medicines market are 
identified. The article rounds off with recommendations which could increase the use of generic 
medicines in Italy. 
METHODOLOGY 
LITERATURE REVIEW 
A literature review has been carried out to explore the current situation of the Italian generic medicines 
market in October 2013. The following databases were searched: Pubmed and Embase. The search 
strategy was developed using combinations of different MeSH terms relevant to the subject. The 
following search terms were used: Italy; drugs, generic; health policy; cost control; cost containment; 
drug costs; drug legislation: economics, pharmaceutical; pharmacy administration; reimbursement 
mechanism; pharmaceutical services and legislation & jurisprudence.  
Studies could be published in English, French, Italian or Dutch. Additional articles were found by a 
review of the reference lists of identified articles and articles known to the authors. The publication 
date was restricted to January 1997 until October 2013, as there was no definition of generic 
medicines before this date. 
INTERVIEWS 
To get a better understanding of the more specific dynamics of the Italian generic medicines market, 
which cannot be found in the literature, interviews have been with managers of generic medicine 
companies in Italy. Additionally, their opinion was asked on the most important barriers limiting the use 
of generic medicines and suggestions which could increase the use of generic medicines. 
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RESULTS 
MARKET ACCESS 
The term ‘generic medicine’ was only introduced into Italian legislation by the 1995 Budget Law, which 
defined a generic medicine as “a product no longer protected by a patent or Supplementary Protection 
Certificate, with the same ingredients, bio-equivalence, form and indication as the originator, marketed 
under the INN either with or without the manufacturer’s name” [10]. Since 2003, this definition has 
been extended to all off-patent products, including those marketed before the patent has expired (i.e. 
copies) [11].  
Patent protection was only introduced in 1978, which was rather late compared to other European 
countries [11]. Complementary Protection Certificates, which allowed for an extension of the original 
patent protection of up to 18 years to compensate for the time between the filing of the patent and the 
granting of the marketing authorization, were introduced by the Italian government in 1991 [10]. The 
introduction of these Complementary Protection Certificates was just before the European 
Commission enforced the European Supplementary Protection Certificate in 1993, which harmonised 
patent protection in the European Union. However, a large number of marketed active ingredients in 
Italy profited from this national Complementary Protection Certificate, as around 400 active ingredients 
obtained one between 19 October 1991 and 2 January 1993 [10]. As a result, many active ingredients 
in Italy profited from longer patent protection periods compared to other European countries, as shown 
in Table 1 [1]. To align with other European countries, Complementary Protection Certificates in Italy 
are being reduced by 6 months every 2 years since 2004 [12]. At this moment, the problem has almost 
disappeared, as around 99% of the older Italian Complementary Protection Certificates have already 
expired. 
[Insert table 1 about here] 
The late introduction of patent protection, the existence of Complementary Protection Certificates, and 
more recently also the spread of ‘co-marketing’ strategies (i.e. the same active ingredient marketed by 
different companies through different brands under the originator license) have created an important 
market for copies in Italy (i.e. branded products equivalent to originator medicines launched before 
parent expiry) [11]. Although copies legally fall within the definition of a generic medicine since 2003, 
their presence constitutes a barrier to market entrance of true generic medicines. Therefore, it is  
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important to distinguish between ‘copies’, ‘branded generics’ and ‘pure generics’ (i.e. company 
branded: international non-proprietary name (INN) + company name) [11].  
According to the Pharmaceutical Sector Inquiry in 2009, the average time for a generic medicine to 
obtain a marketing authorisation in Italy was approximately 6.5 months, which was somewhat below 
the EU average of 7 months [13;14]. 
Patent linkage (i.e. the practice of linking the patent status of the originator medicine to decisions on 
marketing authorizations of generic medicines) has been a long-standing problem in Italy. Following a 
revision of their industrial-property code in 2010, a generic applicant could only start the registration 
procedure 1 year before the expiration of any protection on the active substance (i.e. patent and 
Complementary or Supplementary Protection Certificate). As this was not conform to Directive 
2001/83/EC, the European Commission finally issued a formal call on 26 January 2012 for Italy to 
comply with the EU rules on the marketing authorization of generic medicines [15-17]. Within days, the 
Italian government changed this code to fully comply with the European Directive [18]. However, the 
adoption of Italy’s newly-passed “Balduzzi Decree” in November 2012 introduced another form of 
patent linkage. Following Article 11 of this Decree, medicines, which are ‘equivalent’ to reference 
medicines still protected by patents or Supplementary Protection Certificates, cannot be classified as 
reimbursable by the Italian NHS [18]. 
PRICING 
Prices for reimbursable medicines (‘class A’) are determined through negotiation between the 
manufacturer and AIFA while free pricing is applied for non-reimbursable medicines (‘class C’, usually 
OTC products) [14]. If generic medicines wish to be listed in the same patient co-payment class, their 
prices have to be at least 20% lower than those of their comparable originator products [1;2;14;19]. 
However, this percentage of 20% is only theoretical, as the actual price of a generic medicine is the 
result of negotiations between the manufacturer and AIFA and usually ends up around 60% lower on 
average [20]. 
Since 1 July 2013, a new, voluntary system for pricing and reimbursement of generic medicines has 
been introduced in Italy. In this system, the price of the first generic medicine will be automatically 
determined based on two criteria: the price of the originator medicine at time of application; and the 
level of pharmaceutical expenditure of that medicine in the three years prior to the expiry of the patent. 
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Different tiers of pharmaceutical expenditure have been identified, with corresponding discount 
percentages (see Table 2). A generic medicine will be granted automatic pricing and reimbursement 
approval if the requested price is below this discounted maximum price. This fast track is available for 
companies alongside the classic negotiation with AIFA [21]. 
[Insert Table 2 about here] 
In general, prices of medicines in Italy are amongst the lowest in Europe due to pricing and 
reimbursement regulation to control costs [14]. The price level of generic medicines in Italy is also low 
compared to other European countries [22;23]. A recent study by IMS, which compared the average 
price level of generic medicines between France, Germany, Italy, Spain and United Kingdom 
demonstrated that average prices of generic medicines in Italy were the lowest of the studies countries 
[24]. Price differences between generic and originator medicines vary substantially, depending on the 
active substance, ranging from 0% to 65% [22;23]. 
 In order to control the pharmaceutical budget, a budget ceiling for expenditures of both retail (11.35%) 
and hospital budget (3.5%) as part of total of public health expenditures has been agreed by the Italian 
government. In case of overspending, the private sector and the regions are asked to cover the deficit, 
respectively [25] . Initially, prices of medicines were automatically reduced in case of overspending of 
the retail budget. In 2005, for instance, a 4.4% price cut was agreed on the public prices of all 
reimbursed medicines, including, for the first time in Italy, generic medicines [26-28]. Since then, 
generic medicines have been the subject of several mandatory price cuts imposed by authorities (i.e. 
12% in 2009, 12.5% in 2010 and 14% in 2011) [12;25] [Personal communication EGA]. More recently, 
pharmaceutical companies have been faced with paybacks (i.e. companies have to pay back a share 
of their revenues) to cover the deficit in the retail budget. These paybacks are calculated per 
pharmaceutical company on their level of expenditures during last year [28]. In this way, small and fast 
growing companies (e.g. generic companies) are disproportionally targeted. For instance, generic 
medicines companies’ payback in 2010 represented 21.4% of total payback of all pharmaceutical 
companies, while their market share by value was only around 8.4% [Personal communication EGA]. 
REFERENCE PRICING 
A reference pricing system has been implemented by Italian authorities in September 2001 for 
reimbursable off-patent pharmaceuticals. The Italian system groups pharmaceuticals with the same 
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active substance, route of administration, pharmaceutical formulation, unit dosage and number of units 
in one reference group. Initially, the reference price was calculated as the average price (weighted by 
volume sales) of all equivalent medicines whose price did not exceed that of the most expensive 
generic medicine [2;6;25;29;30]. This reference price was modified rapidly and since December 2001, 
the reference price is calculated as the lowest price among equivalent products available in the 
regional distribution network [1;11;29]. The difference between the reference price and the actual price 
of the medicine is then to be paid by the patient, so-called co-payment [1;5;11]. A monthly revision of 
the reference groups and reference prices is provided for in the legislation [1;6]. In response to the 
introduction of reference pricing in Italy, originator medicines reduced their prices drastically but only 
after several months [11;29]. 
In contrast to other reference pricing systems in Europe, the Italian reference pricing system applies to 
equivalent medicines with the same unit dosage and number of units. Reimbursement limits may 
consequently differ significantly between different pack sizes of the same active ingredient, depending 
on the different competitive pressure and subsequent pricing strategies of manufacturers [29]. In 
addition, reference prices may also slightly differ between the regions, as reference prices are based 
on the local supply in the regional distribution network [29]. 
Re-allocation of demand, a well-known consequence of reference pricing systems based on active 
substance in the literature [31], has been a problem in the Italian market. As a consequence of tough 
price competition in the off-patent market, large pharmaceutical companies may redirect their 
promotional efforts towards more profitable “me-too medicines”, which are not included in the 
reference pricing system [11;31]. A good example of this was the case of ranitidine, one of the main 
off-patent products. Originator and co-marketed copies kept their prices high compared with the prices 
of the generic versions. This resulted in a decrease of their market shares but this eroded volume did 
not go to the generic versions only. A clear rise in the sales of medicines with the same therapeutic 
indications still under patent (i.e. proton pump inhibitors) was observed [11;31]. Estimates of the 
Ministry of Health pointed out that these practices increased overall public pharmaceutical expenditure 
by 3.1% in 2003 [11]. A recent study confirmed the decrease of the medicine prices after the 
introduction of the reference pricing system and demonstrated a positive correlation between the 
number of generic products and the extent of the decrease. However, in contrast to earlier studies, this 
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study did not observe an increased re-allocation of demand in response to the introduction of the 
reference pricing system [25]. 
To increase the awareness of the reference pricing system, a ‘Transparency List’ has been 
established to inform health care professionals since 2001. This ‘Transparency List’, which is 
published on a monthly basis, reports all reimbursable off-patent drugs and their reference prices, 
grouped by active ingredients, route of administration, pharmaceutical form, unit dosage and number 
of units [2;5;29]. 
PHYSICIANS 
Italian physicians generally have a negative attitude towards generic medicines [32;33]. Several tools, 
such as prescribing guidelines, the ‘Transparency List’, etc., have been developed at national level to 
assist physicians to prescribe generic medicines. It is, however, up to the regional authorities to 
oversee the enforcement of these tools. In addition, no budgetary restrictions are applied to physicians 
at national level [1]. 
Many regions and/or local health units have adopted policies to increase the prescribing of cost-
effective medicines (i.e. generic medicine or cheapest equivalent), such as monitoring prescribing 
activities of general practitioners, providing feedback to physicians’ prescribing behavior, etc [1;20].  
Campania, for instance, has introduced minimum levels of generic prescription in five therapeutic 
categories which account for most reimbursement costs in that region [Personal communication EGA]. 
However, due to the decentralization of pharmaceutical policy, generic medicine policies can differ 
substantially from region to region. 
Physicians can freely choose to prescribe by brand name, the name of the generic product or INN [1]. 
General practitioners are, however, obliged by law to inform patients on the existence of cheaper 
alternatives in case of a prescription of off-patent medicines [26]. Since 2012, it is even obliged by law 
to indicate on the prescription that a brand-name drug can be substituted if a generic alternative exists. 
Physicians opposed heavily this new policy and the Italian Federation of General Practitioners even 
recommended against the use of prescribing software which supported this policy [32].  Since 2012, 
physicians are obliged to prescribe by INN for patients treated for the first time for a chronic disease, 
or being treated for a new episode of a chronic pathology  [6] [Personal communication EGA & Assogenerici]. 
However, physicians retain the liberty to write the name of a brand-name medicine or a generic 
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medicine with a company name on a prescription, in addition to the INN. In this case, pharmacists are 
obliged to dispense the lowest priced medicine with this INN, irrespective of the name the physician 
indicated on the prescription, unless the patient is prepared to pay the difference between the 
reference price and the price of the prescribed medicine. 
PHARMACISTS 
In Italy, margins for reimbursable originator medicines and biosimilars differ from the margins for 
reimbursable generic medicines. For reimbursable originator medicines and biosimilars, the wholesale 
margin consists of 3% of the pharmacy retail price net while the pharmacy margin is 30.35% of this 
pharmacy retail price net. For reimbursable generic medicines, the wholesale margin consists of 3% of 
the pharmacy retail price net while the pharmacy margin can vary from 30.35% to 38.35%, as 
community pharmacies and wholesalers should divide an extra margin of 8% according to market 
forces in case of purchase of pure generics. In case of direct purchase from the industry, the margin 
for generic medicines consists of 41.35% [34;35]. A deadline of 1 January 2015 has been set by the 
Italian government to reform the remuneration of pharmacists, with the aim of introducing a fee-for-
service remuneration [Personal communication Assogenerici 
Pharmacists in Italy have been obliged to apply a statutory discount/rebate on pharmacist margins for 
medicines reimbursed by the NHS since 1997 (see Table 3) [1]. Since 2003, pharmacist margins for 
generic medicines priced at or below the reference price level are exempted from this statutory 
discount/rebate [30]. Due to this statutory discount/rebate which pharmacies have to grant the NHS, 
pharmacies say that their margin system is ‘regressive’. Nonetheless, the current remuneration system 
in Italy offers very little support for the delivery of low-priced medicines [11]. 
[Insert table 3 about here] 
As of 1 January 2005, off-patent medicines (branded or unbranded medicines) included in the 
‘Transparency List’ and with a price correspondent to the reference price are exempted from the 
discount/rebate for the NHS. This was meant to financially stimulate pharmacists to promote the use of 
generic and less expensive equivalent medicines [1;11]. Since 2009, any negotiation between 
pharmacies and generic manufacturers (not originators) is forbidden. Discounts to pharmacies are 
thus limited to the additional 8% margin which they can earn by purchasing the generic medicines 
directly from the manufacturer [12;20]. 
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Generic substitution is allowed for pharmacists since 2001. Pharmacists are obliged to propose 
substitution to the patient in case of a prescription of a medicine priced above the reference price. In 
case of substitution, pharmacists are allowed to substitute the prescribed medicine with the cheapest 
available equivalent medicine with patients’ agreement. Physicians can also prevent substitution by 
indicating ‘non-substitutable’ on the prescription form [11;20;25]. Generic substitution is not practiced 
that often, as out of the total amount of medicines prescribed as “brand”, 35% are dispensed as 
generic medicines and 65% remain “brand”. The most common reason for this is the frequent use of 
the non-substitutable clause [Personal communication Assogenerici].   
PATIENTS 
With the introduction of the reference pricing system in 2001, a co-payment was introduced whereby 
patients have to cover the difference between the price of a more expensive pharmaceutical and the 
reference price. Prescription fees (named ‘tickets’), where patients had to pay a fixed amount per 
prescription and/or pack, were abolished by the national authorities at the beginning of 2001. As of 
2002, many regional authorities have reintroduced these tickets in order to contain their 
pharmaceutical expenditures within the planned ceiling of 11.35% of total health expenditures [1;5]. 
Italian patients reportedly have a general preference for originator medicines over generic medicine 
due to concerns on product quality and safety [37]. Additionally, the term “generico” in Italian is 
associated with ‘copy’ or ‘false’, which does not support the confidence in generic medicines. An 
information campaign on generic medicines for physicians, patients, and pharmacists was launched in 
May 2001 by the Ministry of Health in collaboration with the consumers’ association “Altroconsumo”. 
This campaign aimed to inform all on the technical and economic characteristics of generic medicines 
and on the functioning of the reference pricing system [1;2]. In 2007, AIFA conducted pro-generic 
pharmaceutical media campaigns, targeted at patients [1]. 
DISCUSSION 
Uptake of generic medicines in Italy is limited compared to other European countries [7]. The 
regulatory framework in Italy does not support the development of the generic medicines market: 
patent linkage; concentration on prices of generic medicines; a payback system which 
disproportionally targets generic medicines companies; and a lack of effective demand-side policies 
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targeted at physicians, pharmacists and patients have all contributed to the slow growth of the Italian 
generic medicines market. 
Patent linkage has been a long-standing barrier for uptake of generic medicines in Italy. Only back in 
2012, the Italian government had to alter their industrial property code to comply with the EU rules on 
marketing authorisation of generic medicines, as Directive 2001/83/EC explicitly states that the patent 
status of originator medicines may not influence decisions on marketing authorisation, pricing and 
reimbursement of generic medicines [15;38]. However, the introduction of the “Balduzzi Decree” in 
November 2012 once again introduced a form of patent linkage, as medicines cannot be classified as 
reimbursable if the reference medicine is still protected by patents of Supplementary Protection 
Certificates [16-18].  Article 11 of this decree is subsequently not only in opposition with the European 
Directive, it also constitutes a missed opportunity for savings. Without reimbursement, patients are 
unlikely to choose for the generic medicine instead of the reimbursed originator medicine, with a 
higher cost for the third-party payer. 
To control increasing pharmaceutical expenditures, a budget ceiling on both hospital and retail 
expenditures has been implemented by the Italian government [25]. In the past, prices of medicines 
were automatically reduced in case of overspending of the retail budget. As a result, generic 
medicines faced with several mandatory price cuts over the last years [26-28]. The Italian government 
focused on the prices of generic medicines , while they were generally amongst the lowest in Europe 
[22;23]. However, previous research has demonstrated that the price level of generic medicines is 
associated with their market share [39].  As the business model of the generic medicines industry is 
based on the supply of high volume at low prices, these low price levels of generic medicines in Italy 
might endanger the sustainability of the generic medicines industry if they are not accompanied with 
appropriate measures to increase the volume of generic medicines.  
At this moment, pharmaceutical companies are forced to cover the amount of overspending of the 
retail budget by means of a payback [28]. The current payback, however, disproportionally targets 
small and fast growing companies (e.g. generic companies). So while already contributing to a 
decrease of pharmaceutical expenditures, generic medicines companies are additionally penalized for 
their growth. 
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While the Italian government concentrated on the price level of generic medicines in the past, the 
demand-side has been relatively left aside. The importance of demand-side policies to increase the 
use of generic medicines is, nevertheless, highlighted by the varying generic market shares between 
the regions, which are each responsible for their own pharmaceutical policy. Despite some initiatives 
at national level to assist physicians to prescribe generic medicines (e.g. guidelines, Transparency 
List), most regional governments have failed to implement or enforce effective incentives for 
physicians to prescribe generic medicines (e.g. prescribing budgets, prescribing targets, etc.) [1]. This 
lack of effective incentives, in combination with mainly negative perceptions on generic medicines 
amongst most physicians and the power of originator companies in Italy, make that physicians are not 
stimulated to prescribe generic medicines. At the level of pharmacists, the Italian government has tried 
to stimulate the dispensing of generic medicines by allowing generic substitution, applying 
discount/rebates to make pharmacists’ remuneration regressive and exempting less expensive 
medicines from these discount/rebates [20;25]. However, pharmacists’ remuneration still stimulates 
the dispensing of more expensive medicines and pharmacists have subsequently no incentive to 
dispense a generic medicine [36]. Also Italian patients have a general preference for originator 
medicines due to a variety of reasons: negative perceptions on generic medicines related to quality 
and safety caused by bad press; limited support from physicians; power of the brand; and a bad 
connotation of the term “generico” in Italy. For instance, the amount of copayments paid by patients for 
choosing an off-patent originator medicine instead of a generic medicine in Italy is almost equal to the 
entire value of the Italian generic medicines market [40].  
In times of current economic and financial hardship, the Italian government is increasingly looking for 
ways to contain the escalating health care budget. In that respect, both the Italian government and 
regional authorities in Italy should introduce policies to increase the use of generic medicines, as they 
offer equally high-quality treatment at lower costs, resulting in substantial savings for authorities, third-
party payers and patients [30]. For instance, the expiry of the patent on atorvastatin has saved the 
Italian NHS an estimated €293 million in the first 12 months since the medicine lost patent protection 
[Personal Communication EGA]. An increased use of generic medicines will be especially important in Italy, 
as the current environment of generic medicines (i.e. low prices, low volume) threatens the 
sustainability of the generic medicines industry, and by this means also future competition in the Italian 
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medicines market. Therefore, this article will round off with recommendations to increase the use of 
generic medicines, which have shown to be effective in other European countries. 
RECOMMENDATIONS TO INCREASE THE USE OF GENERIC MEDICINES 
1. Abolish patent linkage 
Patent linkage is a cause for delayed market access to generic medicines and therefore 
constitutes a missed opportunity for savings. As it is not conform to the European Directive, all 
forms of patent linkage should be abolished in Italy. Both the Ministry of Health and AIFA 
should not take into account the patent status of the originator medicine for their decision on 
marketing authorization, pricing or reimbursement of generic medicines.  
2. Exclude generic companies from payback  
The current payback system for pharmaceutical companies in Italy penalizes small and fast-
growing pharmaceutical companies (i.e. generic medicine companies). Generic medicines 
companies should be excluded from the payback system as their growth already contributes to 
a decrease of pharmaceutical expenditure. 
3. Reduce pressure on prices of generic medicines 
Prices of generic medicines in Italy are already amongst the lowest in Europe. However, the 
generic medicines industry will only be able to offer low prices if they are ensured a high 
volume of the market. To maintain the future sustainability of the generic medicines industry in 
Italy, the government must shift their focus from policies to reduce the prices of generic 
medicines towards policies to increase the use of generic medicines.  
4. Improve physicians’ training and education in drug selection 
Physicians’ training and education on generic medicines should be enhanced, as a negative 
perception on generic medicines is common among Italian physicians. The education should 
already start in medical school and continued afterwards by academic detailing programs and 
continuous medical education events, sponsored independent of pharmaceutical companies. 
5. Stimulate physicians to prescribe generic medicines 
- Prescription budgets: Physicians should be financially stimulated to prescribe generic 
medicines. Prescription budgets, whereby physicians are financially penalized/rewarded for 
keeping their budget, might provide a stimulus for physicians to prescribe the most cost-
effective (generic) medicines. 
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- Prescription quota: Prescription quotas, linked with or without a financial reward for 
achieving them, may stimulate physicians to increase their prescribing of generic 
medicines [41]. 
- Enforcement of INN prescribing: Prescribing by INN, in combination with a pharmacist 
remuneration system which makes if financially neutral or attractive to dispense cost-
effective (generic) medicines, may increase the use of generic medicines. This policy shifts 
the power of choice of the medicine from the physician to the pharmacists, without 
affecting their therapeutic freedom. It is, however, important for the regional authorities to 
oversee the effective enforcement of these policies [41]. In addition, prescriptions by INN 
should not include the name of a brand-name medicine or a generic medicine with a 
company name in addition to the INN. This practice might stimulate patients to choose for 
the prescribed medicine instead of the lowest priced medicine with this INN, as that 
medicine is recommended by the physician. 
- Implement electronic prescribing: Electronic prescribing with decision support tools 
systems have shown to increase the prescribing of cost-effective (generic) medicines. 
These systems could also easily integrate prescribing guidelines, enforce prescribing by 
INN, etc [41]. 
- Reduce the use of non-substitution clause: The use of the non-substitution clause to 
prevent generic substitution should be limited to real medical causes. Therefore, it will be 
important that physicians state the medical cause on the prescription form and that the 
regional authorities verify for correctness. 
6. Make pharmacists’ remuneration independent of prices of medicines 
The current pharmacists’ remuneration system in Italy financially penalizes pharmacists for 
dispensing cheaper, generic medicines. Therefore, the Italian government should move away 
from this price-dependent remuneration towards a fee-for-service payment, where pharmacists 
are rewarded for their knowledge and their actions with regards to pharmaceutical care (e.g. 
dispensing fee, counselling patients, first-issue guidance, etc.) [36]. 
7. Introduce substitution targets for pharmacists 
Generic substitution, which is allowed in Italy since 2001, is not practiced that often at this 
moment. Substitution targets for pharmacists might provide an incentive for pharmacists to 
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increase their substitution rate, as shown by the experience in France [42]. Eventually, these 
substitution targets could be linked to their remuneration as an incentive to reach the targets. 
8. Improve perception of generic medicines amongst patients 
Public information campaigns, initiated by the regulatory authorities, should increase Italian 
patients’ perception, awareness and demand for generic medicines. These campaigns should 
focus on the concept of generic medicines: their quality, safety, equivalence and cost-saving 
potential. 
9. Provide financial stimulus for patients to accept generic substitution 
Italian patients should be stimulated to accept generic substitution, as many still refuse to 
generic substitution because of preferences for the originator medicine. A delayed 
reimbursement for patients who refuse generic substitution could be an effective tool to 
increase the acceptance of generic substitution, as the experience has shown in France [43].  
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TABLES 
Table 1: Expiration of patent protection [1] 
Active ingredient Germany United Kingdom Sweden Italy 
Omeprazole 04/1999 03/2002 03/2003 12/2007 
Simvastatin 03/2003 04/2003 02/2003 04/2007 
Amlodipine 03/2004 03/2004 n.a. 12/2007 
Felodipine 12/2000 07/2002 02/2003 12/2008 
n.a.: not available 
 
Table 2: New price (before entry of generic medicine) discount levels applied to generic and biosimilar 
medicines [Personal communication Assogenerici] 
Active ingredient Tier 1 Tier 2 Tier 3 Tier 4 Tier 5 Tier 6 Tier 7 Tier 8 
Level of public pharmaceutical 
expenditure (€ million)* 
0 – 
19,99 
20 – 
39,99 
40 – 
59,99 
60 – 
79,99 
80 – 
99,99 
100 – 
139,99 
140 – 
179,99 
180 and 
over 
Discount percentage, class A drug** 45 47.50 50 55 60 65 70 75 
Discount percentage, class H drug*** 30 31.70 33.30 36.70 40 43.30 46.70 50 
* Pharmaceutical expenditure. For inpatient expenditure, the retail price is taken into consideration. Conversely, 
for hospital and direct distribution of medicines, the ex-manufacturer price is considered. 
** The discount on the price for the products in class A (reimbursable medicines) is calculated on the value of the    
current retail price of the reference product. 
*** The percentage discount on the price for the products in class H (reimbursable, only hospital medicines) is 
calculated on the value of the current ex-manufacturer price of the reference product. 
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Table 3: Discounts paid by pharmacies in favour of NHS [1] 
 
Urban and rural pharmacies, non 
subsidized Subsidized rural pharmacies 
Price range Turnover NHS > 
€258,228.45 
Turnover NHS 
< €258,228.45 
Turnover > 
€387,342.67 
Turnover < 
€387,342.67 
< €25.82 3.75%+2.25% 1.5% 3.75%+2.25% 
1.5% 
€25.83 – €51.65 6%+2.25% 2.4% 6%+2.25% 
€51.66 – €103.28 9%+2.25% 3.6% 9%+2.25% 
€103.29 - €154.94 12.5%+2.25% 5% 12.5%+2.25% 
> €154.94 19%+2.25% 7.6% 19%+2.25% 
NHS: National Health Service 
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FIGURES 
 
Figure 1: Generic market shares of the total pharmaceutical market in European countries, 2011 (or 
nearest year) 
 
 
Figure 2: Generic market shares of the 100% reimbursed prescription market in 21 Italian regions 
(January – July 2013) 
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